Drug Sponsors

Plasmatech Biopharmaceuticals to acquire Abeona Therapeutics

Friday, May 8, 2015 12:24 PM

PlasmaTech Biopharmaceuticals, a Texas-based biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has entered into a definitive agreement to acquire Abeona Therapeutics, a company engaged in the development and commercialization of therapies for patients with lysosomal storage diseases. The company will issue to Abeona Therapeutic members a total of 3,979,761 common shares upon closing of the transaction, and up to an additional $9 million in performance milestones, in common stock or cash, at the company’s option.

More... »


Gilead Sciences acquires EpiTherapeutics

Thursday, May 7, 2015 12:24 PM

Gilead Sciences, headquartered in Foster City, Calif., has acquired EpiTherapeutics, a privately held Danish company, for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand.

More... »


Eli Lilly plans innovation center in Massachusetts

Thursday, May 7, 2015 12:22 PM

Eli Lilly plans to establish a new drug delivery and device innovation center in Cambridge, Mass.—a strategic location it says will help attract top scientists and bioengineers, as well as enhance Eli Lilly's local business development presence.

More... »

Alexion to acquire Synageva

Wednesday, May 6, 2015 02:56 PM

Cheshire, Conn.-based Alexion Pharmaceuticals will acquire Synageva, a biopharmaceutical company based in Lexington, Mass., for $115 in cash and 0.6581 Alexion shares for each share of Synageva, implying a total per share value of $230 based on the nine-day volume-weighted average closing price of Alexion stock through May 5.

More... »

Teva provides additional detail on proposed acquisition of Mylan

Wednesday, May 6, 2015 02:51 PM

Teva Pharmaceutical Industries has released an updated investor presentation in connection with its proposed combination with Mylan, which will be filed with the Securities and Exchange Commission (SEC).

More... »

OPKO Health acquires EirGen Pharma

Wednesday, May 6, 2015 02:46 PM

OPKO Health, a multinational biopharmaceutical and diagnostics company, has acquired EirGen Pharma, a specialty pharmaceutical company focused on the development and commercial supply of high-potency, high-barrier-to-entry pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries and more than 40 others around the world.

More... »

Tobira Therapeutics completes merger with Regado Biosciences

Wednesday, May 6, 2015 02:45 PM

Tobira Therapeutics, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and immuno-inflammatory diseases, has merged with Regado Biosciences. Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing. Together with approximately $33 million net cash on Regado's balance sheet, the combined company has approximately $70 million in cash to advance clinical development of first-in-class dual CCR2/CCR5 inhibitor cenicriviroc (CVC), which is being evaluated in the phase IIb CENTAUR clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH) and liver fibrosis.

More... »

Teva completes acquisition of Auspex Pharmaceuticals

Wednesday, May 6, 2015 02:39 PM

Teva Pharmaceutical Industries has completed the acquisition of Auspex Pharmaceuticals through the successful tender offer for all of the outstanding shares of common stock of Auspex at $101 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. The acquisition is expected to enhance Teva’s revenue and earnings growth profile and strengthen its core central nervous system franchise. Auspex now is a wholly owned subsidiary of Teva.

More... »

Can-Fite subsidiary OphthaliX to acquire Improved Vision Systems

Monday, May 4, 2015 01:25 PM

Can-Fite BioPharma, an Israeli biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, has announced its subsidiary, OphthaliX, has signed a non-binding term sheet to acquire Israel-based Improved Vision Systems (IVS).

More... »

Massachusetts Life Sciences Center awards 11 companies tax incentives for 1,075 new jobs

Thursday, April 30, 2015 11:58 AM

The Massachusetts Life Sciences Center (MLSC), an investment agency that supports life sciences innovation, research, development and commercialization, has awarded $19 million in tax incentives to 11 life sciences companies. The recipients have committed to creating 1,075 new jobs in the Commonwealth in 2015.

More... »

CWWeekly

July 6

FDA sued by advocacy groups seeking hepatitis C trials data

Google to test health-tracking wristband to collect clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs